Policy
Government policy moves that are still pending or under review.
Some headlines describe a policy that isn't a policy yet. Policy items are government moves that are proposed, pending or under review, and the hard part is telling official documents from news reports about them.
Here is one example, as of October 25, 2026. The White House Office of Management and Budget's review page lists an HHS/FDA item titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) with a received date of October 14, 2026. [V] AP and CNBC reported on it on October 15. [S] We found no FDA document describing what the policy says. A listing under review is not a final policy, and we update our posts when an official text appears.
Evidence labels: [V] verified in a primary document, [S] secondary source. Reviewed October 25, 2026.
Posts in this topic
- FDA
- Advisory committee
- Policy
Where peptide regulation stands right now: a plain-English timeline
A plain-English timeline of peptide regulation as of October 25, 2026: what FDA documents show, what is only reported, and what is still pending.
- Policy
- FDA
This week in peptide policy: October 19–25, 2026
A quiet week for official peptide and compounding actions, October 19-25, 2026, with the reported HHS interim policy still under White House review.
- Wellness
- FDA
- Policy
From insulin to Ozempic: a timeline of how peptide medicines went from niche to mainstream
A dated timeline of how peptide medicines went from insulin to GLP-1 drugs, and how that changed the money, the FDA rules and public interest.
Common questions
Is the interim peptide policy in effect?
Not as far as we can verify. As of October 25, 2026, OMB's page shows the item under review and we found no published FDA text. [V]
Who has reported on it?
AP and CNBC reported on October 15, 2026. We treat those as secondary sources. [S]
How will I know when something changes?
Each post is dated and says "as of." When an official document appears, we update the post and log material changes on the Corrections page.
Key terms in plain English
- OMB review
- Federal agencies send some planned actions to the Office of Management and Budget for review before publication.
- RIN
- Regulation Identifier Number, used to track a federal regulatory item.
- Interim policy
- A stopgap approach while longer rulemaking is pending.
Primary sources behind this page
- OMB/OIRA review record, RIN 0910-ZD94 (received Oct. 14, 2026)
- AP News report on peptides policy (secondary) (Oct. 15, 2026)
- CNBC report on peptides policy (secondary) (Oct. 15, 2026)